Virtual Library

 x 
My Library Virtual Library FAQ

Start Your Search

F. Dane



Author of

  • +

    P1.09 - Poster Session 1 - Combined Modality (ID 212)

    • Event: WCLC 2013
    • Type: Poster Session
    • Track: Combined Modality
    • Presentations: 1
    • +

      P1.09-021 - Is PET/CT a better tool than CT in response evaluation and follow-up of stage III non-small cell lung cancer after chemoradiotherapy? (ID 3220)

      09:30 - 09:30  |  Author(s): F. Dane

      • Abstract

      Background
      Although pretreatment evaluations are well defined for the diagnosis of stage III NSCLC, we have very little data about the follow-up of these patients after completion of therapy. No documented standards for surveillance were set in the NCCN, ACCP or ESMO guidelines. To determine if there is a survival difference in stage III NSCLC patients who were followed by PET/CT or CT after chemoradiotherapy.

      Methods
      Data from 50 patients who were treated with CRT in Marmara University Medical Oncology clinics between 2003-2012 were retrospectively reviewed. All patients were followed-up by CT or PET/CT. Median age was 57 (range 29-73 years), 90% were male, and PS was 0 in 74%. Adenocarcinoma was seen in 28% and squamous cell carcinoma in 48%. PET/CT was done in 86% of patients during metastatic workup. Median follow-up was 17 months. Median overall survival for all patients was 26 months (range 3-70 months) and progression free survival was 10 months (3-63 months).

      Results
      PET/CT was used in 58% of the patients to evaluate response and was done a median of 6 months after the first treatment. Eight patients had complete, 23 had partial response and 4 had progressive disease. Median survival was 18 months in patient who were followed by CT scans, whilst the survival in the group who had PET/CT was 30 months (p:0.098). Thirtythree patients relapsed on follow-up; of these 28 presented with symptoms, 17 was detected with CT, 5 with MRI of brain and 12 with PET/CT.

      Conclusion
      Response evaluation with PET/CT after CRT in stage III NSCLC might prolong survival in this selected group of patients. But during the follow-up period PET/CT might not be as beneficial as expected, because most of the patients present with symptoms on relapse. Further clinical well designed studies should be done in this field, because usage of PET/CT for follow-up is increasing in the entire world. PET/CT might be unnecessary in the follow-up of stage III NSCLC patients after initial response evaluation.

  • +

    P3.13 - Poster Session 3 - SCLC (ID 202)

    • Event: WCLC 2013
    • Type: Poster Session
    • Track: Medical Oncology
    • Presentations: 1
    • +

      P3.13-001 - Could Pretreatment PET-CT Standart Uptake Values Have a Role in the Response to Treatment and the Survival in Patients with Small Cell Lung Cancer? (ID 666)

      09:30 - 09:30  |  Author(s): F. Dane

      • Abstract

      Background
      It is of great importance for treatment optimization to know before the initiation of treatment the different variables that may be used to help determine the result in the oncological diseases. It has been shown in preveious studies that have been performed that standard uptake values obtained in PET-CT carried out before the treatment in various cancer types enable us to make predictions regarding the tumor’s “aggressiveness”, response to treatment and survival. In this study, we researched the predictive role of pretreatment SU values of the patients with SCLC in determining the response to treatment and the survival.

      Methods
      Ninty patients were enrolled into this study, with whom we had follow-up in our center due to SCLC, and in whom pretreatment PET-CT was performed. The SU value of primary tumor was then determined. The relationship between these values and response to treatment is examined through ROC analysis and the cut-off value, effective and thus the determination to the response to treatment is identified. In the patient group, age, gender, stage, performance status, response to treatment, and effect of SU values upon response to treatment and survival are studied.

      Results
      Ninty patients were enrolled into the study. Median follow-up period is 11 (1-43) months, and the median age is 58 (39-83). Ninety percent of patients are male and the diseases in 37% of were noted to be of limited-stage. All patients received platinum+etoposide chemotherapy once every 21 days, as median amount of treatments to cure was 6 (3-7). When ROC analysis was carried out the SU value, suitable for determining the response, is found to be 10. The sensitivity of this value is found 85.7% (CI 95%; 63-96), the specificity was found to be 61.8% (CI 95%; 49-73) (AUC: 0.783; p: 0.0001). The overall response rate (complet response+partial response) is 59.1% in the other patients, while this rate is 93.3% in patients with involvement above the cut-off value(p:<0.0001). The response rates are higher in patients with age greater than or equal to 60 years old (p:0.047). No significant relationship is found between gender, stage and performance status, and the response to treatment. In the survival analyses carried out, median disease-free survival is found to be 9 months (SE:1; 95% CI: 8-10), and median general survival was determined to be 17 months (SE:3; 95% CI: 12-22). When single and multivariate analysis are carried out, the positive impact/effect of limited-stage disease and response to treatment upon the progression-free survival is determined (p<0.05). The fact that SU value is higher than cut-off value, affects the progression-free survival positively borderline (p:0.085). As a result, this is effective upon general survival, and studied using single and multivariate analysis. It is seen that only the response rates affect the general survival positively (p<0.05).

      Conclusion
      PET-CT is used in SCLC frequently for staging purposes. The data obtained in PET-CT may have a role in determining the prognostic characteristics of the disease as well as the response to treatment.